SNGX Soligenix, Inc.
Soligenix, Inc. (SNGX) is expected to report earnings on November 6, 2026, before the market open. The consensus earnings estimate is a loss of $0.12 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +5.3% since its last earnings release on August 7, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Soligenix, Inc.
Soligenix Inc is a clinical stage biopharmaceutical company engaged in developing products to treat serious inflammatory diseases and where there remains an unmet medical need, as well as developing biodefense vaccines and therapeutics.
Sector
Healthcare
Industry
Biotechnology